{"id":70781,"date":"2026-05-12T11:03:24","date_gmt":"2026-05-12T11:03:24","guid":{"rendered":"https:\/\/medsbase.com\/?post_type=product&#038;p=70781"},"modified":"2026-10-15T10:33:57","modified_gmt":"2026-10-15T10:33:57","slug":"hgh-fragment-176-191","status":"publish","type":"product","link":"https:\/\/medsbase.com\/it\/product\/hgh-fragment-176-191\/","title":{"rendered":"Frammento HGH 176-191"},"content":{"rendered":"<p><!-- medsbase-tldr-answer --><\/p>\n<div style=\"background: #fff8e1; border-left: 4px solid #f5a623; padding: 18px 22px; margin: 18px 0; border-radius: 4px;\">\n<h3 style=\"margin: 0 0 8px 0; font-size: 16px; color: #1a4a6b;\">Risposta rapida \u2014 Cos'\u00e8 il frammento HGH 176-191?<\/h3>\n<p style=\"margin: 0;\"><strong>Frammento HGH 176-191<\/strong> \u00e8 un peptide sintetico di 16 amminoacidi corrispondente ai residui C-terminali 176-191 dell' <a href=\"https:\/\/medsbase.com\/it\/hgh-191aa\/\">ormone della crescita umano<\/a>. In published studies it retains the lipolytic (fat-mobilising) and glucose-modulating activity of the parent HGH molecule but lacks GH-receptor binding affinity and therefore does not activate IGF-1 production, chondrocyte signalling, or any of the growth-promoting effects of full-length HGH. Sequence: YLRIVQCRSVEGSCGF. Supplied in 5\u201315\u00a0mg lyophilized vials.<\/p>\n<\/div>\n<div class=\"medsbase-trust-strip\" style=\"background: #f4f8fb; border: 1px solid #d8e3eb; padding: 12px 16px; margin: 16px 0; border-radius: 4px; font-size: 14px;\"><strong>Cosa ottieni con MedsBase:<\/strong> Pharmaceutical-grade lyophilized peptides &middot; HPLC &ge;99% purity (COA on request) &middot; Discreet protective packaging &middot; Worldwide peptide courier &middot; 1,400+ verified <a href=\"https:\/\/medsbase.com\/it\/reviews\/\">recensioni dei clienti<\/a><\/div>\n<p class=\"medsbase-reship-line\" style=\"font-size: 14px; color: #444; margin: 8px 0 18px;\">\ud83d\udce6 Ogni ordine \u00e8 coperto dalla nostra <a href=\"https:\/\/medsbase.com\/it\/medsbase-re-shipment-assurance-policy\/\"><strong>Politica di Garanzia di Rispedizione<\/strong><\/a> \u2014 se il tuo pacco non arriva entro 20 giorni lavorativi, lo rispediamo.<\/p>\n<table class=\"medsbase-spec-table\" style=\"width: 100%; border-collapse: collapse; margin: 18px 0; font-size: 14px;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 8px 12px; text-align: left; width: 30%;\">Specifiche<\/th>\n<th style=\"padding: 8px 12px; text-align: left;\">Dettaglio<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Numero CAS<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">66004-57-7 (Frammento HGH 176-191; distinto da AOD9604 CAS 221231-10-9)<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Formula Molecolare<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">C<sub>78<\/sub>H<sub>125<\/sub>N<sub>23<\/sub>O<sub>23<\/sub>S<sub>2<\/sub><\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Peso molecolare<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">1817.06 Da<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Sequenza<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe (YLRIVQCRSVEGSCGF, 16 amminoacidi; posizioni 176\u2013191 dell'ormone della crescita umano nativo, conservando il ponte disolfuro Cys182\u2013Cys189 della molecola parentale)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Forma<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Polvere liofilizzata (da bianca a biancastra)<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Purezza<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">\u226599% (verificato con HPLC, COA disponibile su richiesta)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Conservazione<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Liofilizzato: 2\u20138 \u00b0C (frigorifero) per lo stock di lavoro; \u221220 \u00b0C per lo stoccaggio a lungo termine di flaconcini non aperti. Ricostituito: 2\u20138 \u00b0C, utilizzare entro ~30 giorni. Proteggere dalla luce. Non congelare e scongelare la soluzione ricostituita.<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Solubilit\u00e0<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Acqua batteriostatica (consigliata) o acqua sterile per finestre d'uso pi\u00f9 brevi<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><!-- \/medsbase-tldr-answer --><\/p>\n<h2>Cos'\u00e8 il Frammento HGH 176-191?<\/h2>\n<p><strong>Frammento HGH 176-191<\/strong> is a 16-amino-acid synthetic peptide corresponding to the C-terminal residues 176 through 191 of native human growth hormone. The fragment was identified through structure-function studies on HGH conducted at Monash University in the 1990s, when investigators systematically truncated and modified the HGH molecule to map the regions responsible for each of its multiple biological activities. The 176-191 region proved to retain the lipolytic (fat-mobilising) and antilipogenic activity of full-length HGH while completely losing the GH-receptor-binding domain that resides in the N-terminal portion of the parent molecule. The well-characterised sequence is YLRIVQCRSVEGSCGF with the native Cys182\u2013Cys189 intramolecular disulfide bridge preserved (these become Cys7\u2013Cys14 within the fragment numbering). Molecular weight 1817.06\u00a0Da, empirical formula C<sub>78<\/sub>H<sub>125<\/sub>N<sub>23<\/sub>O<sub>23<\/sub>S<sub>2<\/sub>. Il Frammento HGH 176-191 \u00e8 strutturalmente e farmacologicamente <strong>distinto da AOD9604<\/strong> \u2014 an analog developed by Metabolic Pharmaceuticals that adds an N-terminal tyrosine substitution (creating Tyr-HGH 177-191) and modifies the disulfide bridge. AOD9604 has its own CAS (221231-10-9) and pharmacological profile and should not be confused with the unmodified 176-191 fragment supplied here. HGH Fragment 176-191 is supplied as a high-purity lyophilized powder for reconstitution with bacteriostatic water. The fragment is <strong>dalla FDA, EMA, MHRA o da qualsiasi altro importante regolatore per uso terapeutico umano. Il DSIP di grado di ricerca venduto qui \u00e8 fornito<\/strong> by the FDA, EMA, MHRA, or any other major regulator for human therapeutic use. For the full-length parent molecule, see our <a href=\"https:\/\/medsbase.com\/it\/hgh-191aa\/\">HGH 191AA<\/a> pagina prodotto. <\/p>\n<h2>Meccanismo d'azione \u2014 Attivit\u00e0 lipolitica senza legame al recettore GH<\/h2>\n<p>Ci\u00f2 che rende meccanicamente distintivo il frammento HGH 176-191 \u00e8 la <strong>separazione della lipolisi dalla segnalazione dell'asse della crescita<\/strong> \u2014 one of the cleanest examples of structure-function dissection in peptide pharmacology studies:<\/p>\n<ul>\n<li><strong>Assenza di legame al recettore GH<\/strong> \u2014 La superficie di legame al recettore GH dell'HGH nativo \u00e8 contenuta nella porzione N-terminale della molecola (regione residui 1-120), non nel frammento C-terminale 176-191. Di conseguenza, il frammento HGH 176-191 NON si lega al recettore dell'ormone della crescita (GHR), NON attiva la segnalazione JAK2\/STAT5, NON induce la produzione epatica di IGF-1 e NON produce alcuno degli effetti promuoventi la crescita, stimolanti i condrociti o contro-regolatori dell'insulina della molecola <a href=\"https:\/\/medsbase.com\/it\/hgh-191aa\/\">HGH 191AA<\/a> molecule. This is the defining negative pharmacological property and the basis for its studies utility as a lipolysis-axis-isolating tool.<\/li>\n<li><strong>Attivit\u00e0 lipolitica preservata<\/strong> \u2014 Published studies has documented that HGH Fragment 176-191 retains the fat-mobilising activity of full HGH at adipocytes. The exact molecular target underlying the lipolytic effect remains an active studies question; proposed mechanisms include direct action on adipocyte beta-3 adrenergic receptors, modulation of hormone-sensitive lipase, and altered fatty-acid oxidation kinetics. The lipolytic signal is preferentially observed in visceral adipose tissue depots in some published rodent studies, paralleling but mechanistically distinct from the <a href=\"https:\/\/medsbase.com\/it\/tesamorelin\/\">Tesamorelin<\/a> visceral-adiposity signal.<\/li>\n<li><strong>Attivit\u00e0 antilipogenica<\/strong> \u2014 In addition to stimulating fat mobilisation, HGH Fragment 176-191 suppresses lipogenic gene expression in adipocyte study models \u2014 reducing the rate of new fat storage in parallel with increasing fat mobilisation. The two effects produce a net negative-fat-balance signal in adipose tissue.<\/li>\n<\/ul>\n<p>The structure-function-decoupling property is the principal scientific reason HGH Fragment 176-191 has remained in active studies despite never reaching regulatory approval as a stand-alone therapeutic. It is a useful tool for users who want to study HGH&#8217;s lipolytic effects independently from its growth-promoting effects \u2014 a separation that is impossible to achieve with full-length HGH or with GH secretagogues that drive endogenous full-length GH release. Plasma half-life is short (~30 minutes); subcutaneous administration is the standard administration route. <\/p>\n<h2>Published Evidence<\/h2>\n<p>HGH Fragment 176-191 is used in clinical contexts that investigate:<\/p>\n<ul>\n<li><strong>Farmacologia della lipolisi degli adipociti<\/strong> \u2014 caratterizzazione del meccanismo lipolitico isolato, studi sull'interazione con il recettore adrenergico beta-3, attivazione della lipasi ormono-sensibile, cinetica della mobilizzazione degli acidi grassi<\/li>\n<li><strong>Obesity and body-composition studies<\/strong> \u2014 preclinical DIO rodent models, body-composition (DEXA\/MRI), regional adipose-tissue depot effects (visceral vs subcutaneous), lipolysis-without-growth-axis-confound studies designs<\/li>\n<li><strong>HGH structure-function studies<\/strong> \u2014 dissezione meccanicistica dei domini di attivit\u00e0 promotori della crescita vs lipolitici all'interno dell'HGH nativo; il frammento 176-191 dell'HGH come strumento canonico \u201csolo lipolisi\u201d, con <a href=\"https:\/\/medsbase.com\/it\/hgh-191aa\/\">HGH 191AA<\/a> come comparatore di attivit\u00e0 completa<\/li>\n<li><strong>Lipogenic gene-expression studies<\/strong> \u2014 differenziazione degli adipociti, formazione delle gocce lipidiche, interazioni con le vie PPAR\u03b3 e SREBP-1<\/li>\n<li><strong>Visceral adiposity studies<\/strong> \u2014 confronti diretti con <a href=\"https:\/\/medsbase.com\/it\/tesamorelin\/\">Tesamorelin<\/a> as the GHRH-axis visceral-fat-reducing tool; published interest in dissecting GH-receptor-dependent vs GH-receptor-independent visceral-fat-loss mechanisms<\/li>\n<li><strong>Glucose homeostasis studies<\/strong> \u2014 unlike full-length HGH, HGH Fragment 176-191 does not produce the insulin-counter-regulatory effects observed with parent HGH; published studies uses this difference to dissect direct GH glycaemic effects<\/li>\n<li><strong>Comparative HGH-axis studies<\/strong> \u2014 benchmarking rispetto a <a href=\"https:\/\/medsbase.com\/it\/hgh-191aa\/\">HGH 191AA<\/a> (precursore a lunghezza intera), <a href=\"https:\/\/medsbase.com\/it\/tesamorelin\/\">Tesamorelin<\/a> (analogo del GHRH per il grasso viscerale), e <a href=\"https:\/\/medsbase.com\/it\/sermorelin\/\">Sermorelin<\/a> \/ <a href=\"https:\/\/medsbase.com\/it\/cjc-1295-with-dac\/\">CJC-1295<\/a> (stimolatori dell'asse GHRH).<\/li>\n<\/ul>\n<p>For broader context on where HGH Fragment 176-191 fits within the growth-axis and adipose-tissue studies landscape, see <a href=\"https:\/\/medsbase.com\/it\/hgh-191aa\/\">HGH 191AA<\/a> come peptide precursore a lunghezza intera, <a href=\"https:\/\/medsbase.com\/it\/tesamorelin\/\">Tesamorelin<\/a> per l'approccio all'adiposit\u00e0 viscerale tramite l'asse GHRH, e <a href=\"https:\/\/medsbase.com\/it\/sermorelin\/\">Sermorelin<\/a> + <a href=\"https:\/\/medsbase.com\/it\/cjc-1295-with-dac\/\">CJC-1295 con DAC<\/a> for endogenous GH-pulse support. Browse the full <a href=\"https:\/\/medsbase.com\/it\/peptides\/\">catalogo peptidi<\/a> per composti correlati. <\/p>\n<h2>Concentrazioni e Dosaggi Disponibili<\/h2>\n<p>MedsBase stocks HGH Fragment 176-191 in three lyophilized vial sizes calibrated to typical protocol lengths. Each strength is available in 10-vial, 20-vial, or 30-vial pack formats with full reconstitution guidance:<\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Dosaggio per Flaconcino<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Caso d'Uso Tipico<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Dimensioni della Confezione<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>5 mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Short protocols, pilot dosing, single-cohort lipolysis studies<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 o 30 fiale<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>10 mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Standard strength, multi-week protocols<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 o 30 fiale<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>15 mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Protocolli a ciclo esteso, costo per mg pi\u00f9 basso, studi su coorti multiple<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 o 30 fiale<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>All three strengths are the same chemical form (lyophilized powder, 99%+ HPLC purity). Higher-mg vials require smaller reconstitution volumes per unit dose, which is useful when users want to minimise injection volume in rodent protocols. <\/p>\n<h2>Come si confronta \u2014 Frammento HGH 176-191 vs HGH 191AA<\/h2>\n<p>Frammento HGH 176-191 e <a href=\"https:\/\/medsbase.com\/it\/hgh-191aa\/\">HGH 191AA<\/a> are a structure-function decoupled pair \u2014 the fragment is literally a piece of the full-length parent. Comparing them isolates the GH-receptor-binding activity (present in full-length, absent in fragment) from the lipolytic activity (present in both). The comparison is one of the cleanest mechanistic dissections available in current growth-axis studies. <\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Criterio<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Frammento HGH 176-191<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">HGH 191AA (a lunghezza completa)<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Lunghezza<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">16 aminoacidi (~1,8 kDa)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">191 aminoacidi (~22 kDa)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Legame al recettore GH<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">No (il dominio di legame \u00e8 N-terminale)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">S\u00ec (molecola a lunghezza completa)<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Induzione IGF-1<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Nessuno<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Induzione epatica sostanziale<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Attivit\u00e0 lipolitica<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">S\u00ec (conservata)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">S\u00ec (attivit\u00e0 completa del genitore)<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Effetti promotori della crescita<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Nessuno<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Sostanziali (peptide anabolico canonico)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Effetto contro-regolatorio dell'insulina<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">No<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">S\u00ec (resistenza insulinica transitoria)<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Emivita plasmatica<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~30 minuti<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~3\u20135 ore<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Uso clinico approvato<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Nessuno<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Multiple indicazioni (Genotropin, Humatrope, ecc.)<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Dosaggio tipico<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">200\u2013500 mcg, 1\u20133 volte al giorno<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">1\u20138 UI per somministrazione<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>For studies interested in isolated lipolysis pharmacology without the confound of GH-receptor-driven growth and metabolic effects, HGH Fragment 176-191 is the canonical &#8220;lipolysis-only&#8221; tool. For studies investigating the full GH\/IGF axis or comparing with secretagogue-driven endogenous GH release, <a href=\"https:\/\/medsbase.com\/it\/hgh-191aa\/\">HGH 191AA<\/a> is the appropriate full-length reference. Many published studies designs use both in parallel arms to dissect which HGH effects depend on GH-receptor signalling vs which arise from the C-terminal lipolytic mechanism. <\/p>\n<h2>Conservazione e ricostituzione<\/h2>\n<p><strong>Prima della ricostituzione:<\/strong> conservare i flaconcini liofilizzati refrigerati a 2\u20138 \u00b0C nella confezione originale per lo stock di lavoro a breve termine. Per lo stoccaggio a lungo termine non aperto, congelare a \u221220 \u00b0C. Il frammento HGH 176-191 liofilizzato \u00e8 stabile sotto refrigerazione fino a 24 mesi e a \u221220 \u00b0C fino a 36 mesi. Evitare cicli di congelamento-scongelamento sulla polvere liofilizzata. Come altri peptidi con ponti disolfuro, l'attivit\u00e0 del frammento dipende dal legame intatto Cys182\u2013Cys189 (numerazione del frammento Cys7\u2013Cys14) \u2014 una manipolazione che interrompe il disolfuro degrada l'attivit\u00e0. <strong>Procedura di ricostituzione:<\/strong> iniettare acqua batteriostatica lungo la parete laterale del flaconcino del peptide (non direttamente sul panetto liofilizzato). Per un flaconcino da 5 mg, 2,0 mL di acqua batteriostatica producono una concentrazione di lavoro di 2,5 mg\/mL \u2014 0,04 mL forniscono 100 mcg; 0,1 mL forniscono 250 mcg; 0,2 mL forniscono 500 mcg. Agitare delicatamente \u2014 non <strong>not<\/strong> scuotere \u2014 e attendere 2\u20135 minuti per la completa dissoluzione. Una soluzione ricostituita correttamente dovrebbe essere chiara e incolore. <strong>Dopo la ricostituzione:<\/strong> conservare refrigerato a 2\u20138 \u00b0C e utilizzare entro 30 giorni per una stabilit\u00e0 ottimale. Non congelare la soluzione ricostituita \u2014 i cicli di congelamento-scongelamento degradano l'integrit\u00e0 del peptide e possono interrompere il legame disolfuro. Scartare qualsiasi flaconcino che presenti torbidit\u00e0, precipitato o scolorimento. <\/p>\n<h2 id=\"faqs\">Domande frequenti<\/h2>\n<h3>What is HGH Fragment 176-191 used for in studies?<\/h3>\n<p>HGH Fragment 176-191 is used in studies investigating isolated adipocyte lipolysis pharmacology, obesity and body-composition regulation without growth-axis confound, HGH structure-function dissection, lipogenic gene-expression regulation, regional adipose-tissue depot effects, and comparative GH-axis vs lipolysis-only studies designs. It is the canonical &#8220;lipolysis-only&#8221; peptide derived from native HGH. The pharmaceutical-grade HGH Fragment 176-191 sold here is <strong>not<\/strong> FDA-approved and is supplied strictly for clinical studies use only. <\/p>\n<h3>In cosa differisce il frammento HGH 176-191 dall'HGH 191AA?<\/h3>\n<p>Il frammento HGH 176-191 \u00e8 composto da soli 16 amminoacidi \u2014 la porzione C-terminale dell'HGH completo a 191 amminoacidi. Questo frammento manca del dominio di legame al recettore GH (che si trova nella porzione N-terminale della molecola originale), quindi NON si lega al GHR, NON induce IGF-1 e NON produce alcuno degli effetti promotori della crescita o contro-regolatori dell'insulina dell'HGH completo. Conserva solo l'attivit\u00e0 lipolitica e antilipogenica. <a href=\"https:\/\/medsbase.com\/it\/hgh-191aa\/\">HGH 191AA<\/a> \u00e8 la molecola originale a lunghezza completa con attivit\u00e0 sia lipolitica CHE sul sistema della crescita. <\/p>\n<h3>In cosa differisce il frammento HGH 176-191 dall'AOD9604?<\/h3>\n<p>Si tratta di <strong>composti distinti<\/strong> that are frequently confused. HGH Fragment 176-191 (CAS 66004-57-7) is the unmodified C-terminal fragment of native HGH. AOD9604 (CAS 221231-10-9) is a modified analog developed by Metabolic Pharmaceuticals \u2014 specifically, AOD9604 adds an N-terminal tyrosine substitution producing Tyr-HGH 177-191, with engineered changes to the disulfide bridge for improved stability and oral bioavailability studies. The two have related but distinct pharmacology. This product is the unmodified 176-191 fragment, not AOD9604. <\/p>\n<h3>What is the typical HGH Fragment 176-191 dose?<\/h3>\n<p>Published preclinical protocols typically use 200\u2013500\u00a0mcg per administration, given subcutaneously 1\u20133 times daily for 4\u201312 week cycles. A 5\u00a0mg vial reconstituted with 2.0\u00a0mL bacteriostatic water yields 2.5\u00a0mg\/mL \u2014 0.04\u00a0mL equals 100\u00a0mcg, 0.2\u00a0mL equals 500\u00a0mcg. <\/p>\n<h3>Il frammento HGH 176-191 \u00e8 approvato dalla FDA?<\/h3>\n<p>No. HGH Fragment 176-191 is not approved by the FDA, EMA, MHRA, or any other major regulator for human therapeutic use. The related compound AOD9604 was investigated in clinical trials for obesity but did not achieve regulatory approval. <\/p>\n<h3>Come deve essere conservato il frammento HGH 176-191?<\/h3>\n<p>Flaconcini liofilizzati: refrigerati a 2\u20138 \u00b0C per scorte di lavoro a breve termine, o \u221220 \u00b0C per lo stoccaggio a lungo termine di flaconcini non aperti. Soluzione ricostituita: refrigerata a 2\u20138 \u00b0C, utilizzare entro 30 giorni. Non congelare la soluzione ricostituita \u2014 i cicli di congelamento-scongelamento degradano il peptide e possono interrompere il ponte disolfuro essenziale Cys182\u2013Cys189. Proteggere sempre dalla luce diretta. <\/p>\n<h3>Come si ricostituisce il frammento HGH 176-191?<\/h3>\n<p>Seguire la procedura di ricostituzione sopra indicata. Aggiungere acqua batteriostatica lungo la parete laterale del flaconcino (non direttamente sulla polvere liofilizzata), agitare delicatamente e attendere 2-5 minuti per la completa dissoluzione. Non <strong>not<\/strong> Agitare delicatamente il flaconcino \u2014 un'agitazione vigorosa pu\u00f2 interrompere il legame disolfuro. Una soluzione correttamente ricostituita \u00e8 limpida e incolore. Per un flaconcino da 5 mg + 2,0 mL di diluente, la concentrazione di lavoro \u00e8 di 2,5 mg\/mL. <\/p>\n<h3>Quali dosaggi sono disponibili su MedsBase?<\/h3>\n<p>MedsBase carries HGH Fragment 176-191 in 5\u00a0mg, 10\u00a0mg, and 15\u00a0mg lyophilized vials. Each strength is available in 10-vial, 20-vial, or 30-vial pack sizes. All vials are supplied at 99%+ HPLC purity with a certificate of analysis available on request. <\/p>\n<h3>Perch\u00e9 il frammento HGH 176-191 non influisce sull'IGF-1?<\/h3>\n<p>The GH-receptor-binding surface of native human growth hormone is located in the N-terminal portion of the 191-amino-acid molecule, not in the C-terminal 176\u2013191 region. Because the fragment lacks the receptor-binding domain, it cannot activate the GH receptor; without GHR activation, the downstream JAK2\/STAT5 signalling cascade that drives hepatic IGF-1 transcription is not engaged. This structural-functional decoupling is the principal scientific reason the fragment retains studies interest as a lipolysis-isolating tool. <\/p>\n<h3>Da dove deriva l'attivit\u00e0 lipolitica se non dal legame al recettore GH?<\/h3>\n<p>The exact molecular target of HGH Fragment 176-191&#8217;s lipolytic action remains an active studies question. Proposed mechanisms include direct interaction with adipocyte beta-3 adrenergic receptors, modulation of hormone-sensitive lipase activity, and altered fatty-acid oxidation kinetics in adipose tissue. The fragment also suppresses lipogenic gene expression, suggesting it acts on multiple adipocyte-specific pathways simultaneously. Published studies continues to characterise the exact receptor or binding-site target. <\/p>\n<h3>Does HGH Fragment 176-191 cause side reported effects?<\/h3>\n<p>Published preclinical studies has documented a notably clean safety profile at typical doses, with the main on-target effect being lipolysis. The absence of GH-receptor binding means none of the GH-axis side effects observed with full-length HGH (transient insulin resistance, joint discomfort, sodium retention, mitogenic signalling) are present. Long-term human safety data is limited because the unmodified fragment has not undergone modern regulatory review (though the related AOD9604 has been investigated more extensively in clinical trials). <\/p>\n<h3>Qual \u00e8 l'emivita del frammento HGH 176-191?<\/h3>\n<p>In preclinical studies, HGH Fragment 176-191 has a plasma half-life of approximately 30 minutes following subcutaneous administration \u2014 shorter than full-length HGH (~3\u20135 hours) due to the smaller molecular size and absence of albumin-binding modifications. The short half-life means typical protocols use multiple daily administrations or continuous-release formulations for sustained-exposure work. <\/p>\n<h3>How long does HGH Fragment 176-191 take to show effects in preclinical studies?<\/h3>\n<p>Acute effects on adipocyte lipolysis and fatty-acid mobilisation are detectable within hours of administration. Body-composition effects in DIO rodent models typically become statistically significant after 2\u20134 weeks of regular dosing and continue to accrue through 8\u201312 weeks of continuous administration. The kinetics are similar to other adipose-tissue-targeted compounds. <\/p>\n<h3>Posso ordinare il frammento HGH 176-191 per la spedizione internazionale?<\/h3>\n<p>S\u00ec. MedsBase spedisce il frammento HGH 176-191 in tutto il mondo dalla nostra rete dedicata di spedizione di peptidi. Gli ordini contenenti solo peptidi si qualificano per il nostro servizio di spedizione autonomo per peptidi. Tutti gli ordini vengono spediti in imballaggi a temperatura controllata con tracciamento completo e sono coperti dal nostro <a href=\"https:\/\/medsbase.com\/it\/medsbase-re-shipment-assurance-policy\/\">Politica di Garanzia di Rispedizione<\/a>. <!-- medsbase-related-alts-v1 --><\/p>\n<h2>Other Peptides for Adipose, Growth-Axis, and Body-Composition Studies<\/h2>\n<ul>\n<li><a href=\"\/it\/hgh-191aa\/\"><strong>HGH 191AA<\/strong><\/a> \u2014 Ormone della crescita umano ricombinante a lunghezza completa \u2014 la molecola genitore di questo frammento<\/li>\n<li><a href=\"\/it\/tesamorelin\/\"><strong>Tesamorelin<\/strong><\/a> \u2014 GHRH analog \u2014 visceral adipose-tissue studies; FDA-approved for HIV-associated lipodystrophy<\/li>\n<li><a href=\"\/it\/cjc-1295-with-dac\/\"><strong>CJC-1295 con DAC<\/strong><\/a> \u2014 Long-acting GHRH analog \u2014 endogenous GH-pulse support<\/li>\n<li><a href=\"\/it\/sermorelin\/\"><strong>Sermorelin<\/strong><\/a> \u2014 GHRH(1-29) analog \u2014 short-acting GHRH use<\/li>\n<li><a href=\"\/it\/ipamorelin\/\"><strong>Ipamorelin<\/strong><\/a> \u2014 Selective growth hormone secretagogue \u2014 clean GH pulse studies<\/li>\n<\/ul>\n<p><!-- medsbase-peptide-guide-cta --><\/p>\n<h2>Approfondimenti<\/h2>\n<div style=\"background: #f4f8fb; border-left: 4px solid #2c7cb0; padding: 18px 22px; margin: 18px 0; border-radius: 4px;\">\n<p style=\"margin: 0 0 8px 0;\"><strong>\ud83d\udcd6 Explore the HGH-axis studies landscape<\/strong><\/p>\n<p style=\"margin: 0;\">Sfoglia l'intera <a href=\"https:\/\/medsbase.com\/it\/peptides\/\"><strong>catalogo peptidi<\/strong><\/a>, con composti correlati all'asse della crescita inclusi <a href=\"https:\/\/medsbase.com\/it\/hgh-191aa\/\">HGH 191AA<\/a> (precursore a lunghezza intera), <a href=\"https:\/\/medsbase.com\/it\/tesamorelin\/\">Tesamorelin<\/a> (analogico del GHRH per l'adiposit\u00e0 viscerale), <a href=\"https:\/\/medsbase.com\/it\/sermorelin\/\">Sermorelin<\/a> e <a href=\"https:\/\/medsbase.com\/it\/cjc-1295-with-dac\/\">CJC-1295 con DAC<\/a> for endogenous-pulse studies.<\/p>\n<\/div>\n<p><!-- pep-seo-v1 --><\/p>","protected":false},"excerpt":{"rendered":"<p>\u2705 Frammento C-terminale a 16-aa dell'ormone della crescita umano<br \/>\n\u2705 Mantiene l'attivit\u00e0 lipolitica, nessun legame con il recettore dell'GH<br \/>\n\u2705 Nessuna induzione di IGF-1 o effetti promotori della crescita<br \/>\n\u2705 Lipolysis-only tool (distinct from AOD9604)<br \/>\n\u2705 Purezza \u226599% HPLC, COA disponibile su richiesta<\/p>\n<p><strong>Frammento HGH 176-191<\/strong> contiene composto peptidico sintetico.<\/p>","protected":false},"featured_media":70959,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[],"product_cat":[5426],"product_tag":[6288,6289,5441],"class_list":["post-70781","product","type-product","status-publish","has-post-thumbnail","product_cat-peptides","product_tag-hgh","product_tag-hgh-fragment","product_tag-peptide","first","instock","shipping-taxable","purchasable","product-type-variable","has-default-attributes"],"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/it\/wp-json\/wp\/v2\/product\/70781","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/it\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/it\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/it\/wp-json\/wp\/v2\/comments?post=70781"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medsbase.com\/it\/wp-json\/wp\/v2\/media\/70959"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/it\/wp-json\/wp\/v2\/media?parent=70781"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/it\/wp-json\/wp\/v2\/product_brand?post=70781"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/it\/wp-json\/wp\/v2\/product_cat?post=70781"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/it\/wp-json\/wp\/v2\/product_tag?post=70781"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}